Fundz

Eikonoklastes Therapeutics, Inc. reported raising $3.18 Million in an initial SEC Form D filing, from an offering of $7 Million

PRIVATEMay 06, 2021$3.2M of $7M raised

Amount Raised

$3.18 Million

$3.18 Million sold, per SEC Form D (first sale May 6, 2021)

Round Type

Venture

CincinnatiBiotechnologyHealthcare

Quick answer

Eikonoklastes Therapeutics raised $3.18 Million in a funding round, dated May 6, 2021. Eikonoklastes Therapeutics is based in Cincinnati, Ohio, United States.

How much did Eikonoklastes Therapeutics raise?
Eikonoklastes Therapeutics raised $3.18 Million in a funding round on May 6, 2021.
What does Eikonoklastes Therapeutics do?
Eikonoklastes Therapeutics is an early stage biopharmaceutical company focused on rapidly advancing innovative medicines for numerous areas of significant unmet clinical need, starting with neurodegenerative diseases.
Where is Eikonoklastes Therapeutics based and how big is it?
Eikonoklastes Therapeutics is based in Cincinnati, Ohio, United States. Fundz records about 8 employees.
Who are the decision-makers at Eikonoklastes Therapeutics?
Fundz holds 1 contact at Eikonoklastes Therapeutics. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Healthcare and Biotechnology around the same time

Companies in the same sectors as Eikonoklastes Therapeutics that raised within 45 days of this round, from Fundz verified event records.

Who to call at Eikonoklastes Therapeutics, and when

A new round usually means Eikonoklastes Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Eikonoklastes Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Eikonoklastes Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Eikonoklastes Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Eikonoklastes Therapeutics

Location

Cincinnati, Ohio, United States

About

Eikonoklastes Therapeutics is an early stage biopharmaceutical company focused on rapidly advancing innovative medicines for numerous areas of significant unmet clinical need, starting with neurodegenerative diseases. We are iconoclasts who are passionate about finding new and better ways to treat disease.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Eikonoklastes Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts12 people are listed at Eikonoklastes Therapeutics. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Eikonoklastes Therapeutics's next move

See what Strategic adds

Eikonoklastes Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.